COPERNICUS
2001
Carvedilol Prospective Randomized Cumulative Survival Study
In 2,289 patients with severe heart failure and EF ≤ 25%, carvedilol reduced all-cause mortality compared with placebo.
Result
- Absolute difference
- 5.6 points
- NNT
- 18
relative risk reduction3595% CI 19-48 · P = 0.00013
Absolute difference and NNT are derived from the event rates.
- Subtopic
- beta-blocker
- Design
- Double-blind placebo-controlled RCT, stopped early for benefit
- Relevance
- Important: one of several pillars.
- Source
- Packer M, et al. N Engl J Med. 2001;344(22):1651-1658.doi 10.1056/NEJM200105313442201
Discussion & critique
Excluded truly decompensated/volume-overloaded patients, so applies to euvolaemic severe HF. Showed beta-blockade is safe and life-saving even in severe (NYHA III-IV) HFrEF, extending beta-blocker use across the severity spectrum.